2 results
Approved WMORecruiting
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…
Approved WMORecruiting
To compare exposure to ciprofloxacin between patients with impaired renal function (eGFR < 30 ml/min/1.73m2) admitted to a general ward in the AMC or OLVG location Oost receiving the revised reduced doses (test), patients with impaired renal…